Deep Creek Pharma Pursuing FDA Approval for Revolutionary Treatment

A pharmaceutical development startup born from local cancer research is getting a boost in its next phase of growth through Greater Winston-Salem Inc.’s BioNest Grant. 

Deep Creek Pharma is developing a next-generation chemotherapy that could replace the current standard of care for many solid tumor indications. Beginning with metastatic colon cancer, Deep Creek anticipates having its first FDA approved medication in approximately 5 years. The company was founded by William Gmeiner, PhD, Professor of Cancer Biology at Wake Forest School of Medicine.

William Gmeiner stated “This treatment is based on novel fluoropyrimidine polymers and is designed to improve outcomes and reduce systemic toxicities in cancer patients.” Currently, targeted therapies for colorectal, pancreatic, and other types of malignancies are not available and immunotherapy is not effective. The new treatment is anticipated to increase the long-term survival rates for these diseases.

“This grant allows us to accelerate critical research and development as we move closer to clinical validation,” says Christopher B. Kelly, CEO of Deep Creek Pharma. “We remain committed to growing in Winston-Salem as we translate research from the lab to the bedside.”

As Deep Creek Pharma progresses toward Phase I clinical trials, the company expects to invest in scientific equipment and laboratory space over the next three years, in addition to creating up to eight new jobs spanning both scientific and administrative roles.

To date, the company has secured more than $2.5 million in federal funding through the National Institutes of Health Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants, along with a $150,000 loan from the North Carolina Biotechnology Center.

“The work happening at Deep Creek Pharma represents exactly the kind of innovation we aim to cultivate,” says Isaac Perry, Head of Biotech and Life Sciences Ecosystem Development for Innovation Quarter and Greater Winston-Salem Inc. “By supporting companies at this stage, we are helping bring breakthrough therapies closer to market while strengthening Winston-Salem’s position as a hub for life sciences innovation.”

The BioNest Fund supports the growth of life sciences companies relocating to or expanding in Winston-Salem and is made possible through the support of the Whitaker Park Development Authority.